FIRST SUBJECT ENROLLED IN PHASE II/III STUDY OF EISAI’S ANTI-MTBR TAU ANTIBODY E2814 FOR DOMINANTLY INHERITED ALZHEIMER’S DISEASE (DIAD), CONDUCTED BY DIAN-TU
TOKYO, Jan. 18, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") introduced at the moment that ...
